BRIEF-Sangamo Therapeutics To Regain Full Rights To Hemophilia A Gene Therapy Program Following Pfizer’S Decision To Cease Development Of Giroctocogene Fitelparvovec

Reuters
31 Dec 2024
BRIEF-Sangamo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> To Regain Full Rights To Hemophilia A Gene Therapy Program Following Pfizer’S Decision To Cease Development Of Giroctocogene Fitelparvovec

Dec 30 (Reuters) - Sangamo Therapeutics Inc SGMO.O:

  • SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A GENE THERAPY PROGRAM FOLLOWING PFIZER’S DECISION TO CEASE DEVELOPMENT OF GIROCTOCOGENE FITELPARVOVEC

  • SANGAMO THERAPEUTICS: INTENDS TO EXPLORE OPTIONS TO ADVANCE PROGRAM, INCLUDING SEEKING POTENTIAL NEW COLLABORATION PARTNER

  • SANGAMO THERAPEUTICS INC: COLLABORATION AND LICENSE AGREEMENT WITH PFIZER WILL TERMINATE EFFECTIVE APRIL 21, 2025

  • SANGAMO THERAPEUTICS INC: ALL TRIAL PARTICIPANTS WILL CONTINUE TO BE MONITORED AS PLANNED DURING TRANSITION PERIOD

Source text: ID:nBw35RTKxa

Further company coverage: SGMO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10